Bispecific T-cell Redirectors as Part of First Line Treatment in Transplant Eligible Multiple Myeloma Patients

This is Phase 2, open-label, multicentre, non-randomised study evaluating participants with newly diagnosed MM eligible for high-dose therapy. The goal of the study is to determine if consolidation with T-cell redirectors - Talquetamab and Teclistamab in sequence will improve the response depth: increase MRD negative CR rate.

Trial Details

NCT ID
NCT06505369
Phase
PHASE2
Sponsor
North Estonia Medical Centre
Status
RECRUITING
Cancer Type
Newly Diagnosed Multiple Myeloma
Interventions
  • Daratumumab
  • Bortezomib
  • Lenalidomide
  • Dexamethasone
  • Talquetamab
  • Teclistamab
Locations (sample)
  • Copenhagen, Denmark|55.67594,12.56553
  • Odense, Denmark|55.39594,10.38831
  • Vejle, Denmark|55.70927,9.5357
  • Tallinn, Estonia|59.43696,24.75353
  • Oslo, Norway|59.91273,10.74609

Key Eligibility Criteria

  • Participant must have documented MM satisfying the IMWG criteria.
  • Newly diagnosed patients eligible for high dose therapy and ASCT.
  • ECOG performance status score ≤2.
  • HIV-positive participants are eligible if they meet all of the following

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Newly Diagnosed Multiple Myeloma Trials on Trialify →